Establishing a new standard for measuring

the brain that is relevant and useful for patients,

doctors, researchers and treatment developing

We address

  • Demyelinating diseases such as adrenoleukodystrophies or multiple sclerosis
  • Neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease
  • Traumatic conditions, such as trauma brain injury or stroke

Our approach is

  • Already actionable in the clinical routine
  • Non-invasive and painless
  • Clinically validated


Our mission is to

  • Identify patients at risk
  •  Improve diagnosis (differential diagnosis, early diagnosis)
  • Monitor and predict disease evolution

Our platform of digital biomarkers

  • Is proprietary
  • Can be employed in daily practice
  • Is used by physicians, hospitals and drug developers

Who are we ?

We are a medtech spin-off from Paris Region Greater Hospital specialist of white matter, a long-underestimated area of ​​interest in neurosciences.

Discover our team

White matter is the key


The importance of white matter  is still underestimated despite representing 80% of the human brain. Its impairment is either a cause or a consequence of many, if not all, neurological conditions such as traumatic brain injury, or Alzheimer’s disease.


We strongly believe that its exploration could lead to major discoveries in neurology, notably in improving disease diagnosis, enabling the faster and successful development of new disease-modifying therapies and, more important, improving the well-being of patients thanks to a better brain care.


The BrainTale-care platform

We have developed an innovative biomarkers digital medical device platform which enables a quantitative and standardized assessment of the integrity of deep white matter to improve brain care.

Derived from diffusion magnetic resonance imaging, these biomarkers are non-invasive measurements providing sensitive and reliable assessments of white matter alterations.

Read more about the product pipeline

Ultimately, the brainTale-care platform and its biomarkers will enable…





BRAINTALE, whose head office is 11 rue de l’Académie 67000 – STRASBOURG, is registered in the Trade and Companies Register under number 840 995 138 RCS STRASBOURG

Last update : 19/04/2023